

USP Excipients Workshop: Impact of Excipient Grade (Q1/Q2) on Bioequivalence of Generic Drug Products (On-Demand)

Art. ID	USP-EXC-WS-03
Unit	Each
Deliverydetails	No Dangerous Good

Description

To investigate changes in excipient grade and the impact of these changes on bioequivalence and bioavailability, FDA has an ongoing research program for generic drugs for various product categories to steer development of guidances and recommendations to industry on excipient selection for generic products. (Webcast 22 minutes)